Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Abstract Background The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antibody-dependent cellular cytotoxicity (ADCC) induced by type I/II anti-CD...

Full description

Bibliographic Details
Main Authors: Alexandra Albertsson-Lindblad, Catja Freiburghaus, Mats Jerkeman, Sara Ek
Format: Article
Language:English
Published: BMC 2019-08-01
Series:Experimental Hematology & Oncology
Subjects:
Mantle cell lymphoma
Antibody-dependent cell death
Ibrutinib
Lenalidomide
CD20 antibody
Online Access:http://link.springer.com/article/10.1186/s40164-019-0141-1

Internet

http://link.springer.com/article/10.1186/s40164-019-0141-1

Similar Items